Neurobiological Technologies Stock Cash And Equivalents
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Neurobiological Technologies' long-term financial health and intrinsic value.
Neurobiological |
Neurobiological Technologies Company Cash And Equivalents Analysis
Neurobiological Technologies' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Neurobiological Technologies Cash And Equivalents | 26.49 M |
Most of Neurobiological Technologies' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurobiological Technologies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Neurobiological Technologies has 26.49 M in Cash And Equivalents. This is 96.77% lower than that of the Biotechnology sector and 94.08% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 99.02% higher than that of the company.
Neurobiological Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurobiological Technologies' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurobiological Technologies could also be used in its relative valuation, which is a method of valuing Neurobiological Technologies by comparing valuation metrics of similar companies.Neurobiological Technologies is currently under evaluation in cash and equivalents category among its peers.
Neurobiological Fundamentals
| Return On Equity | 1.0 | ||||
| Profit Margin | 0.74 % | ||||
| Operating Margin | 0.77 % | ||||
| Current Valuation | (26.24 M) | ||||
| Shares Outstanding | 27.02 M | ||||
| Shares Owned By Institutions | 9.41 % | ||||
| Number Of Shares Shorted | 37.6 K | ||||
| Price To Book | 0.07 X | ||||
| Price To Sales | 0.0004 X | ||||
| Revenue | 6.03 M | ||||
| Gross Profit | 26.35 M | ||||
| EBITDA | 19.54 M | ||||
| Net Income | 4.94 M | ||||
| Cash And Equivalents | 26.49 M | ||||
| Cash Per Share | 0.98 X | ||||
| Book Value Per Share | 1.07 X | ||||
| Cash Flow From Operations | 4.78 M | ||||
| Short Ratio | 0.09 X | ||||
| Target Price | 6.0 | ||||
| Beta | -408.27 | ||||
| Market Capitalization | 10.86 K | ||||
| Total Asset | 2.58 M | ||||
| Working Capital | (73 K) | ||||
| Current Liabilities | 73 K | ||||
| Z Score | 27.29 | ||||
| Net Asset | 2.58 M |
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Neurobiological Stock
If you are still planning to invest in Neurobiological Technologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobiological Technologies' history and understand the potential risks before investing.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |